COVID-19 and emerging viral infections: The case for interferon lambda
Open Access
- 14 April 2020
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 217 (5)
- https://doi.org/10.1084/jem.20200653
Abstract
With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.Keywords
Funding Information
- National Cancer Institute
- National Institutes of Health
- National Institutes of Health (R01AI39512)
- National Institutes of Health (R21AG064479-01)
- Kent State University
- Royal Society
- Wellcome Trust (206200/Z/17/Z)
- Francis Crick Institute
- Cancer Research UK (FC001206)
- UK Medical Research Council (FC001206)
- Wellcome Trust (FC001206)
- UK Medical Research Council
- King’s College London
- Francis Crick Institute
- National Institutes of Health (1R01 AI121066, 1R01DK115217, NIAID-DAIT-NIHAI201700100)
This publication has 20 references indexed in Scilit:
- Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupusProceedings of the National Academy of Sciences of the United States of America, 2020
- Type III interferons: Balancing tissue tolerance and resistance to pathogen invasionThe Journal of Experimental Medicine, 2019
- Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III InterferonsImmunity, 2019
- Type III interferon is a critical regulator of innate antifungal immunityScience Immunology, 2017
- IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil functionNature Immunology, 2017
- Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host FitnessImmunity, 2017
- IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatmentEMBO Molecular Medicine, 2016
- IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β productionThe Journal of Experimental Medicine, 2015
- Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and CoinfectionsJournal of Interferon & Cytokine Research, 2015
- Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway EpitheliaPLoS Pathogens, 2013